Lucentis improves vision for DME sufferers
This article was originally published in Scrip
Executive Summary
Encouraging Phase III results raise hopes for an additional ophthalmic indication for Lucentis. Results presented at the recent American Diabetes Association meeting reveal that Roche's Lucentis (ranibizumab) significantly improves visual acuity among patients with diabetic macular edema (DME). If approved by the FDA, this would give Lucentis a third indication within the US ophthalmic market.